A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial

【24h】

A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial

机译：多中心期II研究评估Nivolumab Plus Paclitaxel Plus Bevacizumab三重组合疗法作为Her2阴性转移乳腺癌患者的一线治疗的疗效：WJOG9917B Newbeat试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal 》 |2020年第2020期| 共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学 ;
关键词

相似文献

外文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019 ,第008期
2. A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：多中心期II研究评估Nivolumab Plus Paclitaxel Plus Bevacizumab三重组合疗法作为Her2阴性转移乳腺癌患者的一线治疗的疗效：WJOG9917B Newbeat试验
3. A multicenter phase Ib/II study for evaluating safety and efficacy of Nivolumab in combination with radiation therapy in patients with HER2-negative metastatic breast cancer (KBCRN-B-002 trial) [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：一种多中心相IB / II研究，用于评估Nivolumab与Her2阴性转移乳腺癌患者的放射治疗组合的安全性和疗效（KBCRN-B-002试验）
4. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial [J] . Christoph Rochlitz, Martin Bigler, Roger von Moos, BMC Cancer . 2016 ,第1期

机译：SAKK 24/09：贝伐单抗联合紫杉醇与贝伐单抗联合节律性环磷酰胺和卡培他滨作为HER2阴性晚期乳腺癌患者的一线治疗的安全性和耐受性-多中心随机III期研究
5. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
6. Prospective Phase II Multicenter Registry of Ablation after Breast Lumpectomy Added to Extend (ABLATE) Intraoperative Margins in the Treatment of Breast Cancer [D] . Klimberg, V. Suzanne. 2017

机译：乳房肿块切除术后消融的前瞻性II期多中心消融术增加了扩大（ABLATE）术中切缘在治疗乳腺癌中的作用
7. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter phase II single arm trial (GIM11-BERGI) [O] . C. De Angelis, D. Bruzzese, A. Bernardo, 2021

机译：Eribulin与Bevacizumab相结合作为HER2阴性转移性乳腺癌的二线治疗在与紫杉醇和Bevacizumab的一线治疗后进展：多中心II期单臂试验（GIM11-BERGI）
8. Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’ [O] . C. De Angelis, D. Bruzzese, A. Bernardo, 2021

机译：勘探为“二林蛋白与Bevacizumab相结合，作为HER2阴性转移性乳腺癌的二线治疗，与紫杉醇和Bevacizumab具有一线治疗后进展：多中心，II期，单臂试验（GIM11-Bergi）'

A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial

著录项

相似文献

相关主题

期刊订阅